Myocarditis induced by durvalumab in a patient with hepatocellular carcinoma: A case report
Abstract Durvalumab is an immune checkpoint inhibitor that targets PD-L1 and is used for malignancies such as hepatocellular carcinoma. Although effective, it may cause immune-related adverse events, including rare cases of myocarditis (0.06% to 1%), which usually appear early. This complication res...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Springer
2025-10-01
|
| Saila: | Saudi Pharmaceutical Journal |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1007/s44446-025-00041-3 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|